title: Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia.
abstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML) has proven to be an example of medical success in the era of targeted therapy. However, imatinib resistance or intolerance occurs in a substantial number of patients. Additionally, patients who have progressed beyond the chronic phase of CML do relatively poorly with imatinib therapy. Mechanisms of imatinib resistance include BCR-ABL point mutations resulting in decreased imatinib binding, as well as mutation-independent causes of resistance such as SRC family kinase dysregulation, BCR-ABL gene amplification, drug influx/efflux mechanisms and other poorly understood processes. The options for therapy in these patients include stem cell transplantation, imatinib dose escalation as well as the use of second-generation tyrosine kinase inhibitors. Dasatinib is a second-generation multi-kinase inhibitor with several theoretical and mechanistic advantages over imatinib. Moreover, several studies have evaluated dasatinib in patients who have progressed on imatinib therapy with encouraging results. Other novel agents such as mTOR inhibitors, bosutinib and INNO 406 have also shown promise in this setting. Although treatment options have increased, the choice of second-line therapy in patients with CML is influenced by concerns surrounding the duration of response as well as toxicity. Consequently, there is no agreed upon optimal second-line agent. This paper reviews the current data and attempts to address these issues.
authors.affiliation: Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
authors.forename: Radhakrishnan
authors.initials: R
authors.lastname: Ramchandren
authors.forename: Charles A
authors.initials: CA
authors.lastname: Schiffer
references.citation: Blood. 2006 Jun 1;107(11):4532-9
references.pmid: 16469872
references.citation: Oncology (Williston Park). 2008 Apr 15;22(4):430-7; discussion 437, 442, 446 passim
references.pmid: 18472616
references.citation: Ann Oncol. 2007 Jun;18 Suppl 6:vi42-6
references.pmid: 17591830
references.citation: Blood. 2008 Feb 15;111(4):1774-80
references.pmid: 18055868
references.citation: Semin Hematol. 2007 Jan;44(1 Suppl 1):S15-24
references.pmid: 17292737
references.citation: N Engl J Med. 2006 Jun 15;354(24):2531-41
references.pmid: 16775234
references.citation: Blood. 2007 Oct 1;110(7):2309-15
references.pmid: 17496201
references.citation: N Engl J Med. 2006 Jun 15;354(24):2542-51
references.pmid: 16775235
references.citation: Blood. 2008 Aug 15;112(4):1005-12
references.pmid: 18477770
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4392-9
references.pmid: 18628453
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3908-14
references.pmid: 17761974
references.citation: Immunol Rev. 2003 Feb;191:107-18
references.pmid: 12614355
references.citation: Leukemia. 2008 Jun;22(6):1200-6
references.pmid: 18401416
references.citation: J Hematol Oncol. 2008 Oct 01;1:15
references.pmid: 18828913
references.citation: N Engl J Med. 2006 Dec 7;355(23):2408-17
references.pmid: 17151364
references.citation: N Engl J Med. 2007 Jul 19;357(3):258-65
references.pmid: 17634461
references.citation: Blood. 2003 Jan 15;101(2):690-8
references.pmid: 12509383
references.citation: Blood. 2007 Apr 15;109(8):3207-13
references.pmid: 17185463
references.citation: Blood. 2004 Jun 15;103(12):4396-407
references.pmid: 14551133
references.citation: Blood. 2007 Mar 15;109(6):2303-9
references.pmid: 17138817
references.citation: Blood. 2007 May 15;109(10):4143-50
references.pmid: 17264298
references.citation: Med Lett Drugs Ther. 2007 Jan 15;49(1252):6-7
references.pmid: 17220814
references.citation: Cancer. 2007 Apr 15;109(8):1556-60
references.pmid: 17342766
references.citation: J Clin Oncol. 2008 Jul 1;26(19):3204-12
references.pmid: 18541900
references.citation: Blood. 2007 Jun 15;109(12):5143-50
references.pmid: 17317857